Jia Shi Tang: The related matters are currently in progress

Securities Star News: Jiasitang (002462) responded to questions of concern from investors on the investor relations platform on April 02.

Investor: After the group acquisition by Tongrentang, when will the approvals and share transfer be completed? Is there a clear timetable?

Jiasitang Secretary to the Board: Hello, investor. Thank you for your attention to the company. The relevant matters are being advanced. If there is any progress, the company will strictly fulfill its information disclosure obligations and communicate with investors in a timely manner.

Investor: The company’s pharmaceutical commercial gross margin has been relatively low for a long time. What specific measures will the company take in the future to reduce costs, improve efficiency, and enhance profitability?

Jiasitang Secretary to the Board: Hello, investor. Thank you for your attention to the company. On the one hand, the company continues to optimize its business structure, strengthen the expansion and improvement of its core businesses, further strengthen the sales and distribution of pharmaceuticals and medical devices, consolidate its market position, expand its business coverage, and strengthen cooperation with manufacturers, etc., to enhance the company’s market competitiveness. On the other hand, the company continuously strengthens internal management effectiveness, improves operational efficiency, optimizes resource allocation, strictly controls costs and expenses, ensures the company’s steady operations, and safeguards the security and stability of state-owned assets.

Investor: Could I ask whether the company’s dividend policy will be increased? What commitments will be made for the dividend payout ratio in the coming years?

Jiasitang Secretary to the Board: Hello, investor. Thank you for your attention to and support for the company. The company’s dividend policy will be determined in accordance with the provisions of the company’s articles of association, based on profitability and capital needs. For details, please refer to the relevant announcements.

The above content has been compiled from publicly available information by Securities Star and generated by an AI algorithm (Cybersecurity Record No. 310104345710301240019). It does not constitute investment advice.